These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21366364)

  • 1. Hepatitis C virus: five-year follow-up of patients with sustained virological response.
    Urquijo JJ; Diago M
    Rev Esp Enferm Dig; 2011 Feb; 103(2):53-5. PubMed ID: 21366364
    [No Abstract]   [Full Text] [Related]  

  • 2. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.
    Pijak MR; Gazdik F; Hrusovsky S
    Hepatology; 2004 Sep; 40(3):760-1; author reply 761. PubMed ID: 15349918
    [No Abstract]   [Full Text] [Related]  

  • 3. [Therapy of chronic Hepatitis C in 2008].
    Niederau C; Kaden T
    MMW Fortschr Med; 2008 Mar; 150(13):31-4. PubMed ID: 18522354
    [No Abstract]   [Full Text] [Related]  

  • 4. [Predictive value of virological response on sustained virological response in hepatitis C patients].
    Zhou YQ; Wang XH; Fan Y; Zhu Y; Tan WT; Mao Q
    Zhonghua Gan Zang Bing Za Zhi; 2009 Dec; 17(12):944-6. PubMed ID: 20038340
    [No Abstract]   [Full Text] [Related]  

  • 5. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Is 24 weeks of peginterferon and ribavirin combination therapy sufficient for the patients with genotype 1 chronic hepatitis C?].
    Song BC
    Korean J Gastroenterol; 2010 Jul; 56(1):59-61. PubMed ID: 20664319
    [No Abstract]   [Full Text] [Related]  

  • 7. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
    [No Abstract]   [Full Text] [Related]  

  • 8. Summaries for patients. Re-treating patients with chronic hepatitis C who have not responded to peginterferon-alpha2b.
    Ann Intern Med; 2009 Apr; 150(8):I-34. PubMed ID: 19380849
    [No Abstract]   [Full Text] [Related]  

  • 9. Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirin.
    Foster GR; Fried MW; Hadziyannis SJ; Messinger D; Freivogel K; Weiland O
    Scand J Gastroenterol; 2007 Feb; 42(2):247-55. PubMed ID: 17327945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic Hepatitis C Infection in Children.
    Pham YH; Rosenthal P
    Adv Pediatr; 2016 Aug; 63(1):173-94. PubMed ID: 27426900
    [No Abstract]   [Full Text] [Related]  

  • 11. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
    J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADVANCE study begins enrollment.
    AIDS Patient Care STDS; 2008 Apr; 22(4):345. PubMed ID: 18422463
    [No Abstract]   [Full Text] [Related]  

  • 14. Sustained virological response to antiviral treatment in chronic hepatitis C patients may be predictable by HCV-RNA clearance in peripheral blood mononuclear cells.
    Coppola N; De Pascalis S; Pisaturo M; Paradiso L; Macera M; Capoluongo N; Alessio L; Stanzione M; Sagnelli C; Minichini C; Sagnelli E
    J Clin Virol; 2013 Dec; 58(4):748-50. PubMed ID: 24140030
    [No Abstract]   [Full Text] [Related]  

  • 15. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 16. Pegylated interferon treatment in HCV genotype 2 and 3 patients refractory to conventional interferon.
    Aziz S
    J Coll Physicians Surg Pak; 2012 Oct; 22(10):615-6. PubMed ID: 23058141
    [No Abstract]   [Full Text] [Related]  

  • 17. Viral dynamics and prediction of response to treatment with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Aguilar Reina J
    Rev Esp Enferm Dig; 2009 Oct; 101(10):665-70. PubMed ID: 19899934
    [No Abstract]   [Full Text] [Related]  

  • 18. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Peg-IFN alpha-2a plus ribavirin be used to treat patients with chronic hepatitis C and normal alanine aminotransferase levels?
    Dusheiko G; Danta M
    Nat Clin Pract Gastroenterol Hepatol; 2005 Mar; 2(3):130-1. PubMed ID: 16265150
    [No Abstract]   [Full Text] [Related]  

  • 20. The evolving treatment of chronic hepatitis C: where we stand a decade out.
    Saadeh S; Davis GL
    Cleve Clin J Med; 2004 May; 71 Suppl 3():S3-7. PubMed ID: 15468610
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.